PriMera Scientific Surgical
Research and Practice
Volume 7 Issue 2 February 2026
ISSN: 2836-0028

PriMera Scientific Publications

Busulfan: Pharmacology, Clinical Applications, and Future Directions

Type: Review Article
Received: October 10, 2025
Published: January 29, 2026

Citation:
Hariom Rajput. "Busulfan: Pharmacology, Clinical Applications, and Future Directions". PriMera Scientific Surgical Research and Practice 7.2 (2026): 39-47.

Hariom Rajput*

Malhotra College of Pharmacy, Bhopal, Madhya Pradesh, India

***Corresponding Author:** Hariom Rajput, Malhotra College of Pharmacy, Bhopal, Madhya Pradesh, India.

Abstract

Busulfan, a bifunctional alkylating agent, remains a cornerstone in hematologic oncology and transplantation medicine despite the advent of targeted therapies. Originally developed for chronic myeloid leukemia, its current primary application lies in myeloablative conditioning for hematopoietic stem cell transplantation (HSCT). Busulfan exerts its cytotoxic effects through DNA cross-linking, inducing apoptosis in rapidly dividing cells. Its pharmacokinetics are influenced by genetic polymorphisms in glutathione S-transferase enzymes, necessitating therapeutic drug monitoring to balance efficacy and toxicity. Clinical advances, including intravenous formulations and pharmacokinetic-guided dosing, have improved safety outcomes. Ongoing research explores liposomal formulations, gene therapy conditioning, and integration into precision medicine frameworks. While toxicity—particularly hepatic veno-occlusive disease and pulmonary fibrosis—remains a concern, innovations in personalized dosing and pharmacogenomics continue to enhance its therapeutic index. This review highlights Busulfan's evolving clinical roles, challenges, and future prospects in oncology and regenerative medicine.

Keywords: Busulfan; Alkylating Agent; Hematopoietic Stem Cell Transplantation; Pharmacokinetics; Therapeutic Drug Monitoring; Myeloablation; Pharmacogenomics; Veno-Occlusive Disease; Gene Therapy; Precision Medicine

Introduction

Busulfan, a bifunctional alkylating agent, has played a pivotal role in the field of hematology and oncology for several decades. Originally synthesized in the early 1950s, Busulfan is primarily recognized for its cytotoxic properties, which have been harnessed for the treatment of chronic myeloid leukemia (CML) and, more recently, as a conditioning agent in hematopoietic stem cell transplantation (HSCT). Despite the advent of targeted therapies and newer chemotherapeutic agents, Busulfan remains indispensable due to its unique pharmacological profile, efficacy, and versatility in various therapeutic regimens. This research paper aims to provide a comprehensive exploration of Busulfan, encompassing its chemical properties, mechanism of action, pharmacokinetics, clinical applications, toxicity profile, and ongoing research. By analyzing the evolution of Busulfan's clinical use, its integration into multimodal therapy, and the challenges associated with its administration, this article seeks to elucidate both the established and emerging roles of Busulfan in contemporary medical practice.

The discussion will further outline future directions and potential innovations that may shape the trajectory of Busulfan utilization in the coming years [1].

Chemical Structure and Mechanism of Action

Chemical Characteristics

Busulfan is a synthetic, bifunctional alkyl sulfonate with the chemical formula C6H14O6S2.



Structure 1: Chemical Structure Busulfan.

Table A: Physicochemical Properties of Busulfan

S. No	*Property Name*	*Property Value*
1	Molecular Weight	246.3 g/mol
2	XLogP3	-0.5
3	Hydrogen Bond Donor Count	0
4	Hydrogen Bond Acceptor Count	6
5	Rotatable Bond Count	7
6	Exact Mass	246.02318051 Da
7	Monoisotopic Mass	246.02318051 Da
8	Topological Polar Surface Area	104 $Å^2$
9	Heavy Atom Count	14
10	Formal Charge	0
11	Complexity	293
12	Isotope Atom Count	0
13	Defined Atom Stereocenter Count	0
14	Undefined Atom Stereocenter Count	0
15	Defined Bond Stereocenter Count	0
16	Undefined Bond Stereocenter Count	0
17	Covalently-Bonded Unit Count	1
18	Compound Is Canonicalized	Yes

Structurally, it is characterized by two methanesulfonate groups attached to a central butane chain. This configuration facilitates its function as an alkylating agent, capable of cross-linking DNA strands. The molecular weight of Busulfan is 246.31 g/mol, and it is typically administered either orally or intravenously, depending on the clinical context.

Mechanism of Action

The antineoplastic activity of Busulfan is primarily attributed to its alkylating properties. Upon entering the cell, Busulfan undergoes spontaneous hydrolysis, generating reactive intermediates that form covalent bonds with nucleophilic sites on DNA. Specifically, Busulfan reacts with the N7 position of guanine residues in DNA, leading to inter- and intra-strand cross-links. These cross-links disrupt the DNA double helix, impeding replication and transcription processes, and ultimately triggering apoptosis in rapidly dividing cells. The cytotoxicity of Busulfan is not cell cycle-specific, although it exerts the greatest effect on cells in the late G1 and S phases. By inducing DNA damage, Busulfan compromises the integrity of the genome, thereby exerting its antitumor effects. However, this non-selective mechanism also underlies the drug's potential for toxicity, particularly in tissues with high proliferative rates, such as the bone marrow, gastrointestinal tract, and reproductive organs [3, 7].

Busulfan's primary mechanism is the cross-linking of DNA through a series of chemical reactions.

1. ***Reactive ion formation***: When busulfan is administered, its two labile methanesulfonate groups are removed by hydrolysis. This creates positively charged, highly reactive carbonium ions.
2. ***DNA alkylation***: These carbonium ions act on the DNA of rapidly dividing cells by alkylating, or adding alkyl groups, to guanine molecules.
3. ***DNA cross-linking***: The drug creates cross-links within the DNA structure, primarily intrastrand cross-links (within a single DNA strand) at specific guanine base sequences. It can also create interstrand cross-links (between two DNA strands).
4. ***Inhibition of replication***: These cross-links inhibit the ability of the DNA double helix to uncoil and separate. Since this process is essential for DNA replication, the cell is no longer able to divide.

Pharmacokinetics and Pharmacodynamics

Absorption and Distribution

Busulfan exhibits variable oral bioavailability, with absorption influenced by factors such as gastric pH, gastrointestinal motility, and concurrent food intake. Intravenous formulations have been developed to circumvent this variability, providing more predictable pharmacokinetics and facilitating precise dosing, especially in the context of HSCT conditioning regimens. Following administration, Busulfan distributes rapidly throughout the body, including the central nervous system (CNS), owing to its moderate lipophilicity. The volume of distribution (Vd) is approximately 0.6-1.0 L/kg, indicating extensive tissue penetration. Plasma protein binding is moderate, with approximately 30% of the drug bound to albumin and other plasma proteins [1].

Metabolism and Elimination

Busulfan is primarily metabolized in the liver through conjugation with glutathione, mediated by the enzyme glutathione S-transferase (GST). The resulting metabolites are further processed and excreted via the urine. The elimination half-life of Busulfan varies considerably among individuals, ranging from 1.5 to 4 hours in adults, but may be prolonged in pediatric or elderly populations. Genetic polymorphisms in GST enzymes, particularly GST A1, can significantly influence Busulfan clearance, leading to inter-individual variability in drug exposure and, consequently, therapeutic outcomes and toxicity risks. This pharmacogenetic variability underscores the importance of therapeutic drug monitoring (TDM) to optimize dosing and minimize adverse effects [10].

Pharmacodynamics

The pharmacodynamic effects of Busulfan are dose-dependent and closely linked to its capacity to induce myeloablation. The drug's cytotoxicity is most pronounced in hematopoietic stem and progenitor cells, making it particularly effective as a conditioning agent prior to HSCT. However, its effect on non-hematopoietic tissues can result in off-target toxicity, necessitating careful dose adjustment and supportive care measures.

Clinical Applications

Historical Use in Chronic Myeloid Leukemia

Busulfan was first introduced into clinical practice in the 1950s as a treatment for CML. At that time, therapeutic options for CML were limited, and Busulfan represented a significant advance due to its ability to induce hematologic remission. Oral Busulfan was administered as a single agent, leading to reductions in leukocyte counts and symptomatic relief. However, the drug did not achieve cytogenetic remission or eradication of the Philadelphia chromosome, and resistance frequently developed with prolonged use. The advent of tyrosine kinase inhibitors (TKIs) such as imatinib has largely supplanted Busulfan as frontline therapy for CML. Nevertheless, Busulfan remains of historical importance, and its long-term follow-up data have contributed to the understanding of disease progression, drug resistance, and secondary malignancies [10].

Conditioning for Hematopoietic Stem Cell Transplantation

The most significant contemporary application of Busulfan is as a myeloablative agent in conditioning regimens for HSCT. Busulfan-based regimens are employed in both allogeneic and autologous transplantation settings, particularly for hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and certain lymphomas [10].

Myeloablative vs. Reduced-intensity conditioning

Traditional myeloablative regimens utilize high-dose Busulfan, often in combination with cyclophosphamide (Bu/Cy) or fludarabine (Bu/Flu). These regimens are designed to eradicate malignant cells, suppress the host immune system, and facilitate engraftment of donor hematopoietic cells. The choice of Busulfan-based conditioning is influenced by factors such as patient age, comorbidities, disease status, and transplant type.

Reduced-intensity conditioning (RIC) regimens have been developed to expand the eligibility of HSCT to older or medically frail patients. In RIC protocols, lower doses of Busulfan are combined with agents such as fludarabine, resulting in less toxicity while maintaining sufficient immunosuppression to enable engraftment. The balance between efficacy and safety is a key consideration in regimen selection [4].

Intravenous vs. Oral administration

The introduction of intravenous Busulfan has addressed many of the limitations associated with oral administration, including erratic absorption and unpredictable plasma levels. IV Busulfan allows for precise dosing, reduced inter-patient variability, and lower incidence of hepatic veno-occlusive disease (VOD). Pharmacokinetic-guided dosing further enhances safety and efficacy, particularly in pediatric populations and high-risk adults.

Use In Other Malignancies

While Busulfan's primary indications are in hematologic disorders, it has been explored in the treatment of other malignancies, including ovarian cancer, testicular cancer, and certain solid tumors. However, its use in these contexts has been limited by the availability of more effective agents and the risk of cumulative toxicity. Investigational protocols continue to assess the potential of Busulfan in combination with novel agents or as part of high-dose chemotherapy regimens for refractory malignancies [1].

Toxicity and Adverse Effects

Hematologic Toxicity

Busulfan-induced myelosuppression is both a therapeutic goal and a principal adverse effect. Pancytopenia, characterized by neutropenia, thrombocytopenia, and anemia, typically ensues within 7-14 days of administration. The duration and severity of cytopenias depend on the dose, schedule, and patient-specific factors. Supportive care, including transfusions and growth factor support, is essential to mitigate the risks of infection and bleeding during the nadir period [6].

Hepatic Toxicity

One of the most serious complications of Busulfan therapy is hepatic VOD, also known as sinusoidal obstruction syndrome. VOD is characterized by hepatomegaly, jaundice, ascites, and weight gain, and can progress to multi-organ failure. The incidence of VOD is higher with oral Busulfan and in regimens containing cyclophosphamide. Risk factors include pre-existing liver disease, prior chemotherapy, and genetic predispositions affecting drug metabolism. Prophylactic measures, such as ursodeoxycholic acid and meticulous fluid management, are employed to reduce the risk of VOD [9].

Pulmonary Toxicity

Busulfan lung, or interstitial pulmonary fibrosis, is a rare but potentially fatal complication associated with chronic exposure. Clinical manifestations include progressive dyspnea, nonproductive cough, and hypoxemia. Radiographic findings reveal diffuse interstitial infiltrates, and histopathology demonstrates alveolar fibrosis. The pathogenesis is believed to involve direct cytotoxicity to alveolar epithelial cells and subsequent inflammatory responses. Early recognition and discontinuation of Busulfan are critical, although the prognosis remains poor once established [7].

Other Organ Toxicities

Busulfan can also impact other organ systems. Dermatologic effects such as hyperpigmentation, alopecia, and rash are relatively common but generally mild. Gastrointestinal toxicity, including nausea, vomiting, and mucositis, may occur, particularly at higher doses. Gonadal toxicity is notable, with a high risk of infertility in both males and females following high-dose regimens. Neurotoxicity, manifesting as seizures, is rare but necessitates prophylactic anticonvulsant therapy, especially in pediatric patients receiving high-dose Busulfan [8].

Long-Term and Delayed Effects

Long-term survivors of Busulfan therapy are at risk for late complications, including secondary malignancies, endocrinopathies (such as hypothyroidism and growth hormone deficiency), and chronic organ dysfunction. The risk of therapy-related myelodysplastic syndrome or acute leukemia is a particular concern following prolonged exposure or combination with other alkylating agents. Lifelong surveillance and multidisciplinary management are essential to address these sequelae.

Pharmacogenomics and Personalized Medicine

Genetic Determinants of Busulfan Metabolism

The metabolism of Busulfan is significantly influenced by genetic polymorphisms in the GST family of enzymes, particularly GST A1 and GST M1. Variability in GST activity can lead to differences in Busulfan clearance and systemic exposure, affecting both efficacy and toxicity. Patients with decreased GST activity are at increased risk for drug accumulation and adverse effects, while those with high activity may experience subtherapeutic exposure and graft failure following HSCT [3, 9].

Therapeutic Drug Monitoring

To address inter-individual variability, therapeutic drug monitoring (TDM) of Busulfan plasma concentrations has become standard practice in many transplantation centers. TDM enables individualized dosing, aiming to achieve target area under the curve (AUC) values associated with optimal outcomes. Population pharmacokinetic models and Bayesian forecasting tools have been developed to facilitate real-time dose adjustments. The implementation of TDM has been associated with reduced toxicity, improved engraftment rates, and better overall survival in HSCT recipients.

Future Directions in Pharmacogenomics

Advances in pharmacogenomic profiling hold promise for further refinement of Busulfan dosing. Pre-emptive genotyping of GST polymorphisms may enable more precise risk stratification and personalized conditioning regimens. Ongoing research is focused on integrating genetic, clinical, and pharmacokinetic data to develop predictive algorithms that optimize safety and efficacy.

Innovations and emerging applications

Liposomal and targeted formulations

Efforts to enhance the therapeutic index of Busulfan have spurred the development of novel formulations. Liposomal encapsulation has been investigated as a means to improve pharmacokinetic properties, reduce off-target toxicity, and enhance delivery to malignant cells. Early-phase studies suggest that liposomal Busulfan may offer improved tolerability, although further research is needed to establish clinical utility.

Combination Strategies

The integration of Busulfan with novel agents, such as monoclonal antibodies, targeted therapies, and immunomodulators, is an area of active investigation. The rationale for combination strategies is to exploit synergistic cytotoxic effects while minimizing overlapping toxicities. For example, the combination of Busulfan with fludarabine has become standard in RIC regimens, and ongoing trials are evaluating the addition of agents such as venetoclax, a BCL-2 inhibitor, in refractory leukemias.

Gene Therapy and Conditioning

The expanding field of gene therapy has renewed interest in Busulfan as a conditioning agent for patients undergoing autologous gene-modified stem cell transplantation. Busulfan's myeloablative and immunosuppressive properties facilitate engraftment of genetically corrected hematopoietic cells, a critical step in the success of gene therapy for disorders such as thalassemia, sickle cell disease, and severe combined immunodeficiency. Research is ongoing to optimize conditioning protocols that balance efficacy with minimal toxicity, particularly in pediatric populations.

Alternative Dosing and Administration Schedules

Innovations in dosing schedules, such as fractionated administration and pharmacokinetic-guided titration, have been explored to reduce toxicity while maintaining efficacy. Fractionation involves dividing the total Busulfan dose into smaller, more frequent administrations, potentially improving tolerability and reducing peak plasma concentrations. Comparative studies are underway to determine the optimal regimen for various patient populations and disease indications.

Challenges and controversies

Balancing efficacy and toxicity

The principal challenge in Busulfan therapy lies in achieving a therapeutic balance between effective myeloablation and the prevention of life-threatening toxicity. The narrow therapeutic window, inter-patient variability, and the risk of organ damage necessitate vigilant monitoring and individualized care. The development of predictive biomarkers for toxicity and response remains a key research priority.

Busulfan in Pediatric Transplantation

Pediatric patients pose unique challenges in Busulfan administration due to differences in pharmacokinetics, organ maturation, and susceptibility to toxicity. Age-specific dosing algorithms, TDM, and supportive care protocols have improved outcomes, but the risk of long-term sequelae, such as growth retardation and infertility, persists. Research into less toxic conditioning agents and non-myeloablative regimens is ongoing to enhance the safety of pediatric transplantation [4].

Access and Cost Considerations

The cost of Busulfan therapy, particularly intravenous formulations and TDM infrastructure, can be significant. Access to pharmacokinetic monitoring and specialized care may be limited in resource-constrained settings, affecting the feasibility of optimal dosing strategies. Efforts to standardize protocols, develop cost-effective assays, and expand access to quality care are essential to ensure equitable outcomes.

Ethical Considerations

The use of Busulfan as a conditioning agent in gene therapy and transplantation raises ethical questions regarding risk-benefit assessment, informed consent, and long-term follow-up. In pediatric and vulnerable populations, the potential for irreversible toxicity must be weighed against the promise of cure or disease control. Transparent communication, multidisciplinary decision-making, and patient-centered care are fundamental ethical imperatives [1, 3].

Busulfan in the Era of Precision Medicine

Integration with Genomic and Molecular Data

The advent of precision medicine has transformed the landscape of oncology and transplantation, emphasizing the integration of genomic, molecular, and clinical data to guide therapy. For Busulfan, this approach encompasses pharmacogenomic profiling, TDM, and consideration of disease-specific molecular characteristics. Tailored conditioning regimens based on individual patient risk factors and disease biology are increasingly feasible, with the potential to enhance both efficacy and safety.

Role in Novel Therapeutic Paradigms

As targeted therapies and immunotherapies continue to evolve, the role of traditional cytotoxic agents such as Busulfan is being re-evaluated. In certain settings, Busulfan-based conditioning remains essential to facilitate engraftment or achieve disease eradication, while in others, de-escalation or replacement with less toxic agents is possible. The ability to integrate Busulfan into novel therapeutic paradigms, including chimeric antigen receptor (CAR) T-cell therapy and haploidentical transplantation, reflects its enduring relevance [10].

Future Prospects

Looking ahead, the future of Busulfan will be shaped by ongoing advances in drug formulation, personalized dosing, and combination strategies. The development of targeted delivery systems, identification of predictive biomarkers, and integration of real-world data will inform best practices and optimize patient outcomes. As the therapeutic landscape continues to evolve, Busulfan's legacy as a cornerstone of conditioning therapy will likely persist, complemented by innovation and multidisciplinary collaboration.

Conclusion

Busulfan has undergone a remarkable evolution from its origins as an antileukemic agent to its current role as a fundamental component of conditioning regimens in HSCT and gene therapy. Its unique pharmacological properties, coupled with a robust evidence base, have ensured its continued relevance in the management of hematologic malignancies and other disorders. However, the challenges of inter-individual variability, toxicity, and long-term complications necessitate ongoing research and innovation. The integration of pharmacogenomic insights, therapeutic drug monitoring, and personalized care has enhanced the safety and efficacy of Busulfan therapy, particularly in high-risk and vulnerable populations. Emerging applications in gene therapy, targeted delivery, and combination regimens underscore the dynamic nature of Busulfan research and clinical practice. As medicine advances toward greater precision and patient-centeredness, Busulfan's enduring value will depend on the ability to harness its therapeutic potential while minimizing harm. Multidisciplinary collaboration, ethical stewardship, and a commitment to innovation will be essential to realizing the full promise of Busulfan in the years to come.

Abbreviation

S. No.	*Abbreviation*	*Full Form*
1	AML	Acute Myeloid Leukemia
2	AUC	Area Under the Curve
3	Bu/Cy	Busulfan–Cyclophosphamide
4	Bu/Flu	Busulfan–Fludarabine
5	CAR-T	Chimeric Antigen Receptor T-Cell
6	CML	Chronic Myeloid Leukemia
7	CNS	Central Nervous System
8	DNA	Deoxyribonucleic Acid
9	GST	Glutathione S-Transferase
10	GST A1	Glutathione S-Transferase Alpha 1
11	GST M1	Glutathione S-Transferase Mu 1
12	HSCT	Hematopoietic Stem Cell Transplantation
13	IV	Intravenous
14	MDS	Myelodysplastic Syndromes
15	PK	Pharmacokinetics
16	PD	Pharmacodynamics
17	RIC	Reduced-Intensity Conditioning
18	TDM	Therapeutic Drug Monitoring
19	TKI	Tyrosine Kinase Inhibitor
20	Vd	Volume of Distribution
21	VOD	Veno-Occlusive Disease

Acknowledgment

The author expresses sincere gratitude to Malhotra College of Pharmacy, Bhopal, Madhya Pradesh, for providing academic support and resources that facilitated the successful completion of this review article. Special thanks are extended to the faculty and research mentors for their guidance, valuable insights, and encouragement throughout the preparation of this work titled "Busulfan: Pharmacology, Clinical Applications, and Future Directions."

Authors Details

The corresponding author, Hariom Rajput, is affiliated with Malhotra College of Pharmacy, Bhopal, Madhya Pradesh, India. He holds a Master of Pharmacy (Pharmacology) degree and is enrolled under the Enrollment Number: 0143PY24MP22. His academic and research interests include pharmacology, clinical therapeutics, and innovative drug delivery systems.

References

1. Hassan M, Ehrsson H and Ljungman P. "Busulfan pharmacokinetics and therapeutic drug monitoring: Clinical implications in hematopoietic stem cell transplantation". Clinical Pharmacokinetics 59.6 (2020): 747-763.
2. Bartelink IH., et al. "Busulfan dose adjustment for intravenous and oral administration: A review of pharmacokinetic-guided strategies". Biology of Blood and Marrow Transplantation 22.8 (2016): 1443-1452.
3. Chattergoon DS, Saunders EF and Klein J. "Pharmacogenetics of busulfan: The role of glutathione S-transferase polymorphisms".

Therapeutic Drug Monitoring 41.5 (2019): 592-601.

4. Ciurea SO and Andersson BS. "Busulfan in hematopoietic stem cell transplantation: Pharmacology, dosing, and future perspectives". Expert Opinion on Drug Metabolism & Toxicology 15.8 (2019): 671-685.
5. Vassal G., et al. "High-dose busulfan in conditioning regimens: Balancing efficacy and toxicity through therapeutic drug monitoring". Bone Marrow Transplantation 41.6 (2008): 459-465.
6. Zwaveling J., et al. "Population pharmacokinetics of intravenous busulfan in children and adults undergoing stem cell transplantation". Clinical Pharmacology & Therapeutics 103.4 (2018): 652-661.
7. Dvorak CC., et al. "Busulfan dosing in pediatric hematopoietic stem cell transplantation: Advances in pharmacokinetic modeling". Frontiers in Pharmacology 12 (2021): 630921.
8. Andersson BS., et al. "Intravenous busulfan: Optimizing myeloablation while minimizing toxicity in transplant conditioning regimens". Biology of Blood and Marrow Transplantation 23.4 (2017): 558-566.
9. Nguyen L., et al. "Precision dosing of busulfan in hematopoietic stem cell transplantation: The role of pharmacogenomics and modeling". Frontiers in Pharmacology 13 (2022): 828732.
10. De Lima M., et al. "Reduced-intensity conditioning with fludarabine and busulfan: Clinical outcomes and future prospects". Leukemia 32.2 (2018): 392-400.